Free Trial
OTCMKTS:BMXMF

bioMérieux (BMXMF) Stock Price, News & Analysis

bioMérieux logo
$118.91 0.00 (0.00%)
As of 02/21/2025

About bioMérieux Stock (OTCMKTS:BMXMF)

Key Stats

Today's Range
$118.91
$118.91
50-Day Range
$103.09
$121.35
52-Week Range
$93.50
$123.44
Volume
N/A
Average Volume
1,351 shs
Market Capitalization
$14.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

BMXMF Stock News Headlines

Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
bioMérieux S.A. (BMXMF)
Berenberg Bank Keeps Their Buy Rating on bioMerieux (0RUG)
Kepler Capital Reaffirms Their Buy Rating on bioMerieux (0RUG)
See More Headlines

BMXMF Stock Analysis - Frequently Asked Questions

bioMérieux's stock was trading at $106.19 at the start of the year. Since then, BMXMF shares have increased by 12.0% and is now trading at $118.9092.
View the best growth stocks for 2025 here
.

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
2/23/2025
Next Earnings (Estimated)
3/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:BMXMF
CIK
N/A
Employees
14,600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.98 billion
Cash Flow
$5.27 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
N/A
Market Cap
$14.07 billion
Optionable
Not Optionable
Beta
0.80

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:BMXMF) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners